Replacing Worn Out Joints: New Materials and Designs Come to Artificial Hips and Knees  by Erdmann, Jeanne
Chemistry & Biology
InnovationsReplacing Worn Out Joints: New Materials
and Designs Come to Artificial Hips and KneesJeanne Erdmann
DOI 10.1016/j.chembiol.2011.07.006Now that baby boomers are embracing
artificial hip and knees, their ‘‘golden’’
years might be more appropriately re-
named the titanium years.
At one time, the typical joint replace-
ment patients were 70 years or older.
Now, members of the 40+ generation
choose not to live with the pain and de-
creasedmobility of arthritis and are opting
for hip or knee replacements. Younger
patients also want to return to an active
lifestyle with their artificial joints. Such
desires pose a challenge both to the
surgeonswhoneed to choose and implant
the appropriate replacement joint and to
the engineers who design artificial hips
and knees.‘‘Youcan’t tell someonewho is45-years-oldandhadanarthritichip
replaced to stop living their life.’’— Stuart Goodman, M.D., Ph.D.‘‘Baby boomers have different expecta-
tions than our grandparents had,’’ says
Stuart Goodman, M.D., Ph.D., professor
of orthopedic surgery at Stanford Univer-
sity, Palo Alto, California. ‘‘You can’t tell
someone who is 45 years old and had
an arthritic hip replaced to stop living their
life.’’
Joint replacement surgery restores fun-
ction and relieves pain. Goodman adds
that both surgeons and patients alike are
starting to see that implants have good
outcomes and are lasting longer; still, he
tells his patients that even though the
procedure is more common, it is major
surgery that needs significant rehab and
that some adjustments in activity will be
required.
By the time people opt for hip or knee
replacement, their joints have been
damaged by trauma, osteoarthritis, or by
a rheumatoid disease such as rheumatoid
arthritis. In osteoarthritis, the most com-
mon form of arthritis, the cartilage deteri-
orates to the point where the damage rea-
ches the bone. Orthopedic surgeons referto this condition as end-stage joint dis-
ease. Mobility decreases, quality of life
deteriorates, and pain oftenwakes people
in the night.
Twenty years ago, the industry focused
on getting people out of a wheelchair and
getting them mobile again, says Cheryl
Blanchard, Ph.D., Senior Vice President
and CSO at Zimmer, a company head-
quartered in Warsaw, Indiana, that de-
signs andmarkets joint replacement tech-
nologies as well as biologics for early
intervention. She also notes that, as pa-
tients, boomers are more educated and
engaged in their healthcare decision, so
they are much more data driven. ‘‘I think
that’s a good thing.’’The Nex Gen knee is Zimmer’s flagship
product. The science and engineering
that goes into designing, developing,
and commercializing a clinically success-
ful replacement joint takes collaboration
between engineers and orthopedic sur-
geons. A replacement for a joint that
moves needs to imitate the motion and
sliding (articulating) surfaces. The design
process brings together multifaceted dis-
ciplines such as mechanical engineer-
ing, design engineering, and materials
science, as well as quality engineers, ‘‘all
while working in close collaboration with
clinicians who understand what they
need surgically to make this happen and
what their patients need,’’ says Blan-
chard. Designing instrumentation that
goes along with putting implants in is
just as important as getting the implant
right. ‘‘It’s like carpentry in the operating
room,’’ says Blanchard.
In a total knee replacement, for ex-
ample, surgeons remove the damaged
tissue and fix the artificial knee with a
stem, commonly made of titanium, whichChemistry & Biology 18, July 29, 2011replaces the ends of the long bones, such
as the femur. Stems come in various
lengths and are either placed into long
bones without cement or fixed with poly-
methylmethacrylate or PMMA.
The moving articulating surfaces are
most commonly high molecular weight
polyethylene (PE), cobalt chrome, or cera-
mic. These materials are sometimes used
in combination with one another; for ex-
ample, one articulating end can be PE
and another can be metal, so the joint
would be PE gliding against metal. In the
end, the artificial joint needs to withstand
weight bearing and mimic the smooth
glide that cartilage provides for a healthy
joint. One of the changes to materials
over the past decade has been the advent
of PE made from highly cross-linked
polymers. The cross-linking adds another
chemical bond in the polymer chain that
improves wear resistance.
Replacement joints don’t last forever.
One of problems plaguing replacement
joints has been the generation of what is
called wear debris. As the articulating
surfaces move against one another day
after day, year after year, the friction gen-
erates microscopic particles that set off
a chain reaction which can lead to implant
failure.
Microscopic Particles, Major Issues
In about 10% of total hips and knee
replacements, a piece of fibrous tissue
forms between the implant and the tita-
nium stem. That tissue, full of active cells,
contributes to loosening of the implant;
worse, cells in the tissue cause a cas-
cade of damage that leads to a significant
amount of bone loss. Eventually, the
implant loosens to the point so that the
surgeon needs to take the patient back
to the operating room for revision surgery,
which is far more complicated than im-
planting a primary hip or knee.
Goodman has been studying this phe-
nomenon since his surgical residency
more than 30 years ago. His surgical
mentor at the time was implanting aª2011 Elsevier Ltd All rights reserved 817
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patients. Goodman says the concept
was good, but the new joint was essen-
tially a wear debris machine that failed
after 2 to 5 years; however, it provided
Goodman’s mentor and collaborators
with a bounty of wear particles to study.
He continued investigating biological
and molecular processes that leads to
aseptic loosening when he moved to
Stanford in 1985.
Researchers have come to understand
more over the past 30 years about wear
debris. One thing they do know is that
wear particles will never go away; the
idea is to find the right combination of
materials and design that generates fewer
particles.
Many different cells are involved:
macrophages, mesenchymal stem cells,
osteoblasts, and osteoclasts. Goodman’s
research in animal models shows that
macrophages can be recruited from dis-
tant sites in the body. His team has also
shown that cytokines and chemokines
inhibit the response that can repair bone.
Clinically, Goodman says the idea is to
modulate the local reaction and to boost
local tissues to make more bone. For
example, Goodman is a participant in
a clinical trial of Biomet’s E1, an antioxi-
dant-infused polyethylene. Biomet, also
headquartered in Warsaw, Indiana, spe-
cializes in orthopedics, sports medi-
cine, and dental implants. Bill Kolter, Cor-
porate Vice President of Government
Affairs at Biomet, says the objective of
E1 is to increase wear resistance by
reducing oxidative degradation of the
PE and to maintain mechanical proper-
ties. Cross-linking PE via high-dose ra-
diation provides good wear resistance,
says Kolter, but any active free radi-
cals residually left in the material can
become progenitors for oxidative deg-
radation. By doping PE with vitamin
E, Biomet aims to quench those free
radicals.818 Chemistry & Biology 18, July 29, 2011 ª2One Step Ahead
Revision rates for joint replacement are
tracked in several joint registries in Europe
and in Australia. Typically, revision rates
at 1% per year are the standard for hip
replacements set by NICE (National Insti-
tute for Health and Clinical Excellence,
UK). At 5 years, for example, the revision
rate should not exceed 5%. Joints can
fail for reasons other than aseptic loos-
ening such as implant position and the
many individual differences in patients,
including weight, degree of joint damage,
level of activity, and dedication to rehab.
Pam Plouhar, Ph.D., world-wide Vice
President of Clinical Affairs at DePuy
Orthopaedics, says the company’s Pin-
nacle Hip System has a long history of
clinical performance and is designed to
work well with the younger, active pa-
tients who receive hip replacements
today. The revision rates are less than
4% at 5 years and comparable or better
to this class of hip implants overall.
Recently, DePuy had a ‘‘ceramic on me-
tal’’ hip system approved by the FDA.
‘‘We’re always trying to understand
how current innovation impacts the mar-
ketplace and how we can leverage that
to develop better products to meet the
needs of both the surgeons and the pa-
tients,’’ says Plouhar. ‘‘Even though the
performance of the Pinnacle systems
shows less than a 4% revision rate at 5
years, and that is a very good outcome,
we’re always looking to improve the
performance of our products.’’
Zimmer also has a new bone and
growth implant surface called trabecular
metal, which goes on a number of hip
and knee implants in which no cement is
used. The surface that’s exposed to
bone is made from a specialized material
that mimics the microstructure of bone
and is conducive to bone growth. Edward
Greenfield, Ph.D., Professor and Director
of Orthopedic Research at Case Western
Reserve University, is working on the011 Elsevier Ltd All rights reservedosteointegration with Zimmer on their
trabecular metal. Greenfield’s team is
focusing on the hypothesis that bacteria
contribute to aseptic loosening. When
Greenfield first started mentioning his
hypothesis at meetings, his colleagues
took a while to warm to the idea. Now,
many labs have data in data cell culture
and mouse models consistent with that
hypothesis.
A number of other labs have looked at
implants in patients with aseptic loos-
ening and found that many patients have
bacterial biofilm on their implants even
though there are no clinical signs of infec-
tion. That’s why it’s called aseptic. ‘‘That
doesn’t prove that the biofilm is contrib-
uting to loosening; at least it tells you the
bacteria are there and the PAMPS [path-
ogen associated molecular patterns] that
bacteria make are presumably there,’’
says Greenfield.
Greenfield’s team also really wants to
understand how signaling in wear debris
works in cell culture and mice and is
investigating the role the toll-like recep-
tors (TLRs) play. The researchers are
also investigating other bacterial reco-
gnition molecules—some downstream of
TLR receptors and some that work in
parallel. ‘‘If, some day, we really show
that bacteria are important contributors
to aseptic loosening, that suggests that
antibacterial strategies might be useful.
We’re a long way from there,’’ says
Greenfield.
Data from the Norwegian Arthroplasty
Registry support the bacterial hypothesis.
In a study of more than 10,000 primary ce-
mented hip replacements, patients who
were given intravenous antibiotics and
had antibiotics embedded in the bone
cement had fewer revisions.
‘‘It may be that you just have to win the
race,’’ says Greenfield.Jeanne Erdmann (erdmannj@nasw.org) is a sci-
ence writer based in Wentzville, MO.
